{"name":"NiKang Therapeutics, Inc.","slug":"nikang-therapeutics-inc","ticker":"","exchange":"","domain":"nikang.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxOS1d5X2ZDZnQ4dUxnSGdKN0lWTjdHX2JzWWdKMk1vSmczWER5XzVHM0VJX2dpVFBEUk1aYldlQkVwSlZCMHl5UUlUQU15U1ZObUtvLW5JNWVLN1VBZEZtNVB6NWZNQU9yVk5obnpPN3dsQlJMcmItaHFoM29pSVhaeFpSbEFyZjdwSUt2OTNlcHY1eXBxaHFxTFZqMjhfMkktUVhweFZpWktGWW9tclBmT0ZacFhKODlVcVMtd3VZQ09LSVFjM2FfcTlreWlHYjdac1p5czJQRC0zbzZ6Ty1aRW9MWEpHSzhBNlBvZks0d3BQbmV4WFE?oc=5","date":"2026-03-24","type":"pipeline","source":"Barchart","summary":"Metastatic Renal Cell Carcinoma Treatment Pipeline Shows Strong Momentum as 40+ Pharma Companies in the Race | DelveInsight - Barchart","headline":"Metastatic Renal Cell Carcinoma Treatment Pipeline Shows Strong Momentum as 40+ Pharma Companies in the Race | DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxObGhNVTdzVFZ1QUEtVm5SbEJJV0QyX2c4U3NPeUxER3ZlS0JXdHVHdkZMY25HNmotOEVlSzVsTms5LU5Rdk9RM3ZCQWRzVmJTc2lnNkVDclYzSmVKNlM4cnl6bmVEd3Flc1p0Z3VETEdJaUpnNmlscm5IbE4yMGhFODdMMXVyMjd0T0JyM2s4UlFjeUJEWHk4cUdXNWpqOW1JMWtCakVqNGZ5Z205cW1mSW9uakRGbDlpRDQtZXozM1JPand4WWRfYzBsWEpWVFZMNE5WLTJ2VkI2SXZQWEpNNVFhZ2QxejBIX1RrNW1pMVlZWnNybXF1NFp4SW85cmphQWhsaDQ4bUZKR0pySkpaWngwaEw4OUw2WGdEM292RGNPYzdwS3RJRGJSWGREMlQ4ejFDZW40TUJXMks1QWlGaURFZEFzeUE?oc=5","date":"2025-12-11","type":"pipeline","source":"Business Wire","summary":"NiKang Therapeutics Presents Discovery of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader for Cancer Therapy at SABCS 2025 - Business Wire","headline":"NiKang Therapeutics Presents Discovery of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPbFQ4SVVHTFVtQ0h4NGhwQ1pHOEM4Yk9USGplV0FmTXB6cFpyaEpEeGd1OVN5ZGlfeGZkSmhtSk82VnhqMzVGWFZHTUhaNTM0MDB6eGdfTm9Kd0E2dW1IVkF5V2JmUURrY2oyT3hOZl9FejJYRVV4TDYtbTZ1M2h3bDhPY2EzNm1xYlE?oc=5","date":"2024-09-24","type":"trial","source":"Yahoo Finance","summary":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance","headline":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNY0dtN0UxZFpJaWc2X0UtMzJ6dzc4Yl9zVzV2b2x3eWlweWxGdFNIU3RoNEZpRTVRM1hoc05aWHdyMW1XUEQyQTk5cWlrWWE4SU5DYUwwMWtkVjc1b0ZqYTBROTlxZzNMRjYwdUstbVVUM3ZMZUQ3S2xqMGpDQVhmUkhkWEM2akpYMVlMLU1mY21aLWcyekxtN1FkQUNiRDgxUm40RDFjczRReXpfNHczOGdqSXFsTHJEWXFBT2g5dnE3R1IyYnBnNFFLMEVvbjVlTktwak1ZUmpLc241VUpIb1hoNXVNUjNyckhQS0NWcU1JTDRfc0RnMmRMeXQ4NThIRDNENjhLQTBldw?oc=5","date":"2022-05-03","type":"deal","source":"Business Wire","summary":"NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China - Business Wire","headline":"NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater Chin","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2022-01-05","type":"trial","source":"Business Wire","summary":"NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment","headline":"NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1JdTA5X2NPcVZ6THI4bk5OdG8yZTRqbUpXV3c1dFlCckxIM29pV0M0T21raUNTcjU3U2xXTHM2aGhwd19FeklUWXpjVFMwbGh6MjV3R283SWl1OFJFRjZFQ2wyRnFsOGNJUkHSAXJBVV95cUxPR2pBa25WUV9wdDBVeG5tT1JrMHRFQWk3WVV3WjI4bDVEQUszWDQwZVNfSnoyS21aenJEeEN0cXVBVWUxYmZ2TERjb0xZa3pRM21Lb2U2N3RyOFpEc0wzZnpJaXNyS0FqMXZETXlzSG8xT2c?oc=5","date":"2021-06-09","type":"pipeline","source":"Delaware Business Times","summary":"Biotech startup NiKang raises $200M - Delaware Business Times","headline":"Biotech startup NiKang raises $200M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQcDRyY2pXQmoybXVsZEJjalI4RlIyYnlWd1BsRlJpZFFYZks2RGlpS1YxbV9DMzV2M296d19LZXppOHFKZC1fWFhQdGlDbUJwOGlROHB4UXJZcjAweXRkVnBBTjBHWkZTUzFyUVc0Q2FqY0tTb1Q0XzlKczBpc2hIb2QyMVpmT3pRT0RuOVU4YVpkWUs1LTlCalZMV2lidnRrWkFwY1MxQWtEUFo1R0NzR214dkVjSjBvNm5vZg?oc=5","date":"2021-05-26","type":"pipeline","source":"Fierce Biotech","summary":"NiKang's new CFO appointment pays off with $200M fund raise from her previous employer - Fierce Biotech","headline":"NiKang's new CFO appointment pays off with $200M fund raise from her previous employer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNV2V1aFU3cFY5cUQ2MWkyX1N0VnMtTkdfMWJCelFRZUtDcndmS3JiejMxM29LNmtpbE9SX2pNYVl4bW45aFBYUlRaS1VPZTJaeFJabTNvZU9aQVY0QjBoenRDaWlvWnZaZGtkU21QQTVFT2RjRjk0RVUyanFZa1FZei02UDRHa2c5T185MEt6cVdGcko2OERHVGp2TURlXzA0NDhPa1Z0UDFYdW93TjRtS3VReDhaVWM3aEdtVmN6WWlaTzN2cmdOSVdaUFdfTGpfWmR3Q0g3S0FCZV9IMXdxY21TR055eDRmYU1kRi01QzcyUWpRMW5rS3Fpc0tJdlU?oc=5","date":"2020-07-23","type":"deal","source":"Business Wire","summary":"CORRECTING and REPLACING Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib - Business Wire","headline":"CORRECTING and REPLACING Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxQdlRNTDROSGs4aVplUERJNVlvZUREdDNES1VvVVdwOEtIT2l3Z09QSVFEbVV0T3B6d3RTcmZYTENjRldqRTlPQzFqY2h6enZFSG9RYW9XQWNLWHBWVG9JaTJhdmI4RVhhUkhCSWlydVpxNkQwMHFlUElpNlNxTEZZT2F5SVliZXgwLXpVb0xxVW1sMFpmOHF2MHBXeU4tbVg0NXlzMTdYSll6WmJ1bnFISjEzaXZjbzZMc2ZKa00xNmpvb3V6RjF5RHZHeVk2ZmRHVTM1UTN1Z2tQUjBsOGZGYVlhYmhYOVRkR2NUZGpBdXdPeVhrTlZvaGE2SkFTLXp4YjFKcjRfcU5nRE5PRWJTLWVGSG1sR2pHaXhPd1hRdy1IZFhDWDhaTmJEa25PRFVUS2c?oc=5","date":"2020-04-23","type":"deal","source":"Business Wire","summary":"Hansoh Pharma and NiKang Therapeutics Enter into a Development and Commercialization Partnership for a Novel Treatment for Anti-Viral Diseases in China - Business Wire","headline":"Hansoh Pharma and NiKang Therapeutics Enter into a Development and Commercialization Partnership for a Novel Treatment f","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}